HCW 9302 T lymphocyte cell therapy - HCW Biologics
Latest Information Update: 28 Dec 2025
At a glance
- Originator HCW Biologics
- Class T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 28 Dec 2025 No recent reports of development identified for research development in Autoimmune-disorders in USA (Parenteral)
- 28 Dec 2025 No recent reports of development identified for research development in Inflammation in USA (Parenteral)
- 01 Nov 2021 HCW 9302 cell therapy - HCW Biologics is available for licensing as of 01 Nov 2021. https://hcwbiologics.com/pipeline/ (HCW Biologics pipeline, November 2021)